A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IDXX SEC filings page.
Idexx Laboratories Inc (IDXX) reported $4.7B in revenue over the twelve months to Sep 30, 2026, up 11.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
IDEXX turns sales growth into faster cash generation and lower borrowing, with FY2025 revealing a more efficient operating model.
FY2025 revenue grew10.4% while operating income grew20.5% , indicating costs absorbed growth rather than rising in lockstep. Free cash flow grew30.8% while capital expenditures rose only3.1% , so more of the earnings improvement translated into cash available after reinvestment.
Debt-to-equity fell from 0.4x in FY2023 to 0.2x in FY2025, showing the business became less dependent on borrowing even as it expanded. The current ratio was 1.2x in FY2025 while current liabilities grew
Operating cash flow reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Idexx Laboratories Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Idexx Laboratories Inc scores 93/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Idexx Laboratories Inc scores 60/100 on it among other operating companies.
Idexx Laboratories Inc's net debt of $194.8M, being $374.8M of long-term debt less $180.1M of cash, came to 0.13 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Idexx Laboratories Inc scores 75/100 among other operating companies measured the same way.
Idexx Laboratories Inc held $1.23 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.23. Liquidity ranks operating companies on that ratio, and Idexx Laboratories Inc scores 31/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Idexx Laboratories Inc scores 89/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Idexx Laboratories Inc scores 98/100 on it among other operating companies.
Idexx Laboratories Inc scores 23.70, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $53.3B against total liabilities of $1.7B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Idexx Laboratories Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Idexx Laboratories Inc generates $1.12 in operating cash flow ($1.2B OCF vs $1.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Idexx Laboratories Inc earns $35.01 in operating income for every $1 of interest expense ($1.4B vs $38.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Idexx Laboratories Inc generated $1.2B in revenue in Q3 2026. This represents an increase of 9.9% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.
Idexx Laboratories Inc's EBITDA was $442.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.1% from the same quarter a year earlier. Against the prior quarter it is down 5.1%.
Idexx Laboratories Inc reported $317.1M in net income in Q3 2026. This represents an increase of 15.5% from the same quarter a year earlier. Against the prior quarter it is down 6.3%.
Idexx Laboratories Inc earned $4.01 per diluted share (EPS) in Q3 2026. This represents an increase of 17.9% from the same quarter a year earlier. Against the prior quarter it is down 6.1%.
Cash & Balance Sheet
Idexx Laboratories Inc generated $420.8M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 13.4% from the same quarter a year earlier. Against the prior quarter it is up 30.5%.
Idexx Laboratories Inc held $197.5M in cash against $299.9M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Idexx Laboratories Inc's gross margin was 62.9% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Idexx Laboratories Inc's operating margin was 33.1% in Q3 2026, reflecting core business profitability. This is up 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.8 percentage points.
Idexx Laboratories Inc's net profit margin was 26.1% in Q3 2026, showing the share of revenue converted to profit. This is up 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
Idexx Laboratories Inc's quarterly ROE was 17.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.0 percentage points.
Capital Allocation
Idexx Laboratories Inc invested $68.8M in research and development in Q3 2026. This represents an increase of 8.5% from the same quarter a year earlier. Against the prior quarter it is up 5.2%.
Idexx Laboratories Inc spent $112.2M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 53.3% from the same quarter a year earlier. Against the prior quarter it is down 67.7%.
Idexx Laboratories Inc invested $28.9M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 7.0% from the same quarter a year earlier. Against the prior quarter it is up 17.4%.
IDXX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B+9.9% | $1.2B+9.7% | $1.1B+14.3% | $1.1B+14.3% | $1.1B+13.3% | $1.1B+10.6% | $998.4M+3.6% | $954.3M+5.8% |
| Cost of Revenue | $449.9M+6.6% | $437.5M+5.5% | $418.1M+11.5% | $432.5M+12.7% | $421.9M+11.2% | $414.7M+7.9% | $375.0M+1.1% | $383.6M+2.2% |
| Gross Profit | $764.3M+11.8% | $779.1M+12.1% | $722.7M+15.9% | $658.1M+15.3% | $683.4M+14.6% | $694.7M+12.2% | $623.4M+5.1% | $570.7M+8.5% |
| R&D Expenses | $68.8M+8.5% | $65.4M+5.7% | $65.8M+11.4% | $66.8M+15.8% | $63.4M+17.5% | $61.9M+11.6% | $59.1M+12.2% | $57.7M+11.4% |
| SG&A Expenses | $293.1M+10.6% | $288.1M+10.9% | $294.4M+18.8% | $275.7M+9.7% | $265.1M+11.3% | $259.8M-13.4% | $247.8M+2.6% | $251.2M+9.7% |
| Operating Income | $402.3M+13.4% | $425.6M+14.1% | $362.6M+14.5% | $315.6M+20.6% | $354.8M+16.8% | $373.0M+41.4% | $316.5M+5.9% | $261.7M+6.7% |
| EBITDA | $442.9M+13.1% | $466.6M+14.1% | $400.3M+14.2% | $354.3M+20.0% | $391.5M+15.8% | $408.8M+38.1% | $350.6M+6.6% | $295.4M+7.4% |
| Interest Expense | $7.5M-30.0% | $10.2M-10.1% | $7.7M+1.0% | $9.2M+22.8% | $10.7M+38.4% | $11.3M+39.8% | $7.7M-3.1% | $7.5M-19.1% |
| Income Tax | $82.2M+17.1% | $78.8M+15.3% | $77.0M+14.2% | $58.8M+46.1% | $70.2M+6.2% | $68.4M+22.6% | $67.4M+12.5% | $40.2M-10.9% |
| Net Income | $317.1M+15.5% | $338.4M+15.1% | $278.4M+14.7% | $248.2M+14.8% | $274.6M+17.9% | $294.0M+44.6% | $242.7M+3.0% | $216.1M+11.1% |
| EPS (Basic) | $4.02+17.2% | $4.29+17.2% | $3.50+17.4% | $3.11+17.4% | $3.43+21.2% | $3.66+48.8% | $2.98+4.9% | $2.65+13.2% |
| EPS (Diluted) | $4.01+17.9% | $4.27+17.6% | $3.47+17.2% | $3.09+17.9% | $3.40+21.4% | $3.63+48.8% | $2.96+5.3% | $2.62+13.4% |
| Diluted Shares (Avg) | 79M-2.0% | 79M-2.1% | 80M-2.1% | N/A | 81M-2.9% | 81M-2.9% | 82M-2.4% | N/A |
IDXX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.7B+9.5% | $3.4B+3.3% | $3.4B+5.3% | $3.4B+1.7% | $3.4B+1.1% | $3.3B-2.5% | $3.2B-4.2% | $3.3B+1.0% |
| Current Assets | $1.5B+1.6% | $1.5B+10.8% | $1.5B+10.4% | $1.4B+1.0% | $1.5B+3.0% | $1.4B-10.9% | $1.3B-12.3% | $1.4B-6.4% |
| Cash & Equivalents | $197.5M-5.1% | $196.9M+19.6% | $200.5M+22.3% | $180.1M-37.5% | $208.2M-32.6% | $164.6M-59.0% | $164.0M-58.7% | $288.3M-36.5% |
| Short-Term Investments | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventory | $390.9M-0.2% | $391.6M-0.3% | $382.4M-3.4% | $377.8M-1.1% | $391.6M+0.5% | $392.6M+3.3% | $396.0M+1.4% | $381.9M+0.4% |
| Accounts Receivable | $615.8M+8.6% | $627.1M+11.9% | $603.5M+14.4% | $552.4M+16.6% | $566.9M+10.9% | $560.6M+5.1% | $527.5M+4.0% | $473.6M+3.5% |
| Goodwill | $640.5M+54.8% | $410.9M-0.9% | $412.1M+1.1% | $414.0M+2.2% | $413.7M+0.4% | $414.5M+1.6% | $407.5M-0.3% | $405.1M+10.7% |
| Total Liabilities | $1.8B+0.7% | $1.8B-2.3% | $1.8B+3.6% | $1.7B+2.8% | $1.8B+5.4% | $1.9B+2.0% | $1.8B-1.1% | $1.7B-4.4% |
| Current Liabilities | $1.3B+1.0% | $1.3B+5.2% | $1.3B+14.4% | $1.1B+7.6% | $1.3B+24.0% | $1.2B+9.6% | $1.1B+18.7% | $1.1B+12.2% |
| Non-Current Liabilities | $573.7M0.0% | $542.1M-16.4% | $529.5M-15.9% | $596.6M-5.3% | $573.7M-20.7% | $648.1M-9.7% | $629.5M-24.0% | $630.2M-23.5% |
| Long-Term Debt | $299.9M-20.0% | $299.9M-33.3% | $299.9M-33.3% | $374.8M-16.7% | $374.8M-28.6% | $449.8M-14.3% | $449.8M-27.5% | $449.8M-27.8% |
| Total Equity | $1.9B+19.7% | $1.6B+10.5% | $1.6B+7.5% | $1.6B+0.6% | $1.6B-3.5% | $1.5B-7.7% | $1.4B-7.7% | $1.6B+7.5% |
| Retained Earnings | $7.3B+19.2% | $7.0B+19.4% | $6.7B+19.6% | $6.4B+19.9% | $6.1B+20.1% | $5.9B+20.2% | $5.6B+19.1% | $5.3B+20.0% |
Not reported in any period shown, so not listed: Long-Term Investments.
IDXX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $449.7M+11.8% | $347.2M+86.9% | $266.2M+11.9% | $355.8M+35.8% | $402.3M+82.8% | $185.7M-25.2% | $238.0M+19.8% | $262.0M+4.9% |
| Depreciation & Amortization | $40.6M+10.7% | $41.1M+14.8% | $37.7M+10.6% | $38.7M+14.9% | $36.6M+7.3% | $35.8M+11.1% | $34.1M+13.9% | $33.7M+13.3% |
| Stock-Based Compensation | $16.2M+12.5% | $16.1M+8.1% | $16.3M+11.8% | N/A | $14.4M-9.4% | $14.9M-5.1% | $14.6M+1.5% | N/A |
| Capital Expenditures | $28.9M-7.0% | $24.6M-27.7% | $32.0M+6.5% | $29.4M+0.6% | $31.1M+10.8% | $34.1M+2.4% | $30.0M-0.8% | $29.3M-10.1% |
| Free Cash Flow | $420.8M+13.4% | $322.5M+112.7% | $234.3M+12.7% | $326.3M+40.2% | $371.2M+93.4% | $151.6M-29.5% | $207.9M+23.5% | $232.8M+7.1% |
| Investing Cash Flow | -$248.1Mn/m | -$25.5Mn/m | -$33.5Mn/m | -$28.1Mn/m | -$44.9Mn/m | -$33.6Mn/m | -$29.6Mn/m | -$39.8Mn/m |
| Financing Cash Flow | -$200.8Mn/m | -$325.2Mn/m | -$211.4Mn/m | -$355.7Mn/m | -$313.3Mn/m | -$165.6Mn/m | -$330.3Mn/m | -$232.8Mn/m |
| Share Buybacks | $112.2M-53.3% | $346.8M+2.6% | $351.0M-12.4% | $237.8M-3.3% | $240.2M+8.8% | $338.1M+56.9% | $400.9M+159.0% | $246.0M+567.5% |
Not reported in any period shown, so not listed: Dividends Paid.
IDXX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.9%+1.1pp | 64.0%+1.4pp | 63.3%+0.9pp | 60.4%+0.6pp | 61.8%+0.7pp | 62.6%+0.9pp | 62.4%+0.9pp | 59.8%+1.4pp |
| Operating Margin | 33.1%+1.0pp | 35.0%+1.4pp | 31.8%+0.1pp | 28.9%+1.5pp | 32.1%+1.0pp | 33.6%+7.3pp | 31.7%+0.7pp | 27.4%+0.2pp |
| Net Margin | 26.1%+1.3pp | 27.8%+1.3pp | 24.4%+0.1pp | 22.8%+0.1pp | 24.9%+1.0pp | 26.5%+6.2pp | 24.3%-0.1pp | 22.7%+1.1pp |
| Return on Equity | 17.0%-0.6pp | 21.0%+0.8pp | 17.9%+1.1pp | 15.5%+1.9pp | 17.6%+3.2pp | 20.2%+7.3pp | 16.8%+1.7pp | 13.6%+0.5pp |
| Return on Assets | 8.6%+0.4pp | 9.8%+1.0pp | 8.2%+0.7pp | 7.4%+0.8pp | 8.1%+1.2pp | 8.8%+2.9pp | 7.5%+0.5pp | 6.6%+0.6pp |
| Current Ratio | 1.190.0x | 1.17+0.1x | 1.120.0x | 1.23-0.1x | 1.18-0.2x | 1.11-0.3x | 1.16-0.4x | 1.31-0.3x |
| Debt-to-Equity | 0.16-0.1x | 0.19-0.1x | 0.19-0.1x | 0.230.0x | 0.24-0.1x | 0.310.0x | 0.31-0.1x | 0.28-0.1x |
| Liabilities-to-Equity | 0.98-0.2x | 1.13-0.1x | 1.180.0x | 1.090.0x | 1.17+0.1x | 1.28+0.1x | 1.22+0.1x | 1.06-0.1x |
| Asset Turnover | 0.330.0x | 0.350.0x | 0.340.0x | 0.330.0x | 0.330.0x | 0.330.0x | 0.310.0x | 0.290.0x |
| FCF Margin | 34.6%+1.1pp | 26.5%+12.8pp | 20.5%-0.3pp | 29.9%+5.5pp | 33.6%+13.9pp | 13.7%-7.8pp | 20.8%+3.4pp | 24.4%+0.3pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Idexx Laboratories Inc IDXX | FY2025 | $4.3B | $1.1B | 24.6% | $53.3B | 74/100 |
| Agilent Technologies Inc. A | FY2025 | $6.9B | $1.3B | 18.8% | $48.0B | 68/100 |
| Natera, Inc. NTRA | FY2025 | $2.3B | -$208.2M | -9.0% | $39.6B | 52/100 |
| Waters Corp WAT | FY2025 | $3.2B | $642.6M | 20.3% | $43.3B | 71/100 |
| IQVIA Holdings Inc. IQV | FY2025 | $16.3B | $1.4B | 8.3% | $40.5B | 50/100 |
| Mettler-Toledo International MTD | FY2025 | $4.0B | $869.2M | 21.6% | $33.2B | 59/100 |
Where Idexx Laboratories Inc Ranks
Frequently Asked Questions
Idexx Laboratories Inc (IDXX) reported $4.3B in total revenue for fiscal year 2025. This represents a 10.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Idexx Laboratories Inc (IDXX) revenue grew by 10.4% year-over-year, from $3.9B to $4.3B in fiscal year 2025.
Yes, Idexx Laboratories Inc (IDXX) reported a net income of $1.2B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.1B, with a net profit margin of 24.6%.
Idexx Laboratories Inc (IDXX) had EBITDA of $1.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Idexx Laboratories Inc (IDXX) had $180.1M in cash and equivalents against $374.8M in long-term debt.
Idexx Laboratories Inc (IDXX) had a gross margin of 61.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Idexx Laboratories Inc (IDXX) had an operating margin of 31.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Idexx Laboratories Inc (IDXX) had a net profit margin of 24.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Idexx Laboratories Inc (IDXX) has a return on equity of 66.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Idexx Laboratories Inc (IDXX) generated $1.1B in free cash flow during fiscal year 2025. This represents a 30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Idexx Laboratories Inc (IDXX) generated $1.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Idexx Laboratories Inc (IDXX) had $3.4B in total assets as of fiscal year 2025, including both current and long-term assets.
Idexx Laboratories Inc (IDXX) invested $124.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Idexx Laboratories Inc (IDXX) invested $251.2M in research and development during fiscal year 2025.
Idexx Laboratories Inc (IDXX) had a current ratio of 1.23 as of fiscal year 2025, which is considered adequate.
Idexx Laboratories Inc (IDXX) had a debt-to-equity ratio of 0.23 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Idexx Laboratories Inc (IDXX) had a liabilities-to-equity ratio of 1.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Idexx Laboratories Inc (IDXX) had a return on assets of 31.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Idexx Laboratories Inc (IDXX) trades at 45.1x earnings, its market capitalization divided by $1.2B net income, trailing 12 months to September 30, 2026. The market capitalization is $53.3B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Idexx Laboratories Inc (IDXX) trades at 11.4x sales, its market capitalization divided by $4.7B revenue, trailing 12 months to September 30, 2026. The market capitalization is $53.3B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Idexx Laboratories Inc (IDXX) has an Altman Z-Score of 23.70, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Idexx Laboratories Inc (IDXX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Idexx Laboratories Inc (IDXX) has an earnings quality ratio of 1.12x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Idexx Laboratories Inc (IDXX) has an interest coverage ratio of 35.01x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Idexx Laboratories Inc (IDXX) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.